iSpecimen shares surge 14.7% premarket after rapid procurement of 500 flu samples and expanded specimen supply.

iSpecimen surged 14.70% in premarket trading following the announcement of rapid procurement milestones for influenza research, including the collection of approximately 500 influenza swab samples over several weeks to support a customer project. The company also highlighted sustained supply of cerebrospinal fluid and rising demand for Formalin-Fixed Paraffin-Embedded and fresh frozen tissue. Positive customer feedback emphasized specimen quality and documentation, with one client noting intent to credit iSpecimen in publications. These developments underscored the firm’s capacity to meet time-sensitive research needs and reinforced confidence in its biospecimen sourcing capabilities, aligning with the stock’s sharp premarket gain.